Lofacimig

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 20:06:42 GMT 2025` Edited by `admin` on `Wed Apr 02 20:06:42 GMT 2025`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	L55HB62LXD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Lofacimig

Official Name

English

H-gamma1 heavy chain VH-VH-G1(h-CH2-CH3) (1-493) [VH anti-F11 apple 2 domain (Camelus dromedarius IGHV3S45*01 (86.6%)/Homo sapiens IGHV3-66*01 (83.5%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT [9.7.23] (26-34.52-58.97-119)) (1-130) -3-mer (glycyl-alanyl-prolyl)

Preferred Name

English

only-heavy-chain immunoglobulin VH-VH-G1(h-CH2-CH3) dimer, anti-[Homo sapiens F11 (coagulation factor XI, FXI, plasma thromboplastin antecedent, PTA) apple 2 domain] and anti-[Homo sapiens F11 (coagulation factor XI, FXI, plasma thromboplastin antecedent

Common Name

English

Immunoglobulin, biparatropic, anti-(human coagulation factor XI Apple 2 domain) (human-Lama glama monoclonal KN060 single-domain VHH fragment) fusion protein with peptide linker (GAP) fusion protein with immunoglobulin anti-(human coagulation factor XI A

Common Name

English

lofacimig [INN]

Common Name

English

Code System Code Type Description

FDA UNII

L55HB62LXD

Created by admin on Wed Apr 02 20:06:42 GMT 2025 , Edited by admin on Wed Apr 02 20:06:42 GMT 2025

PRIMARY

NCI_THESAURUS

C211782

Created by admin on Wed Apr 02 20:06:42 GMT 2025 , Edited by admin on Wed Apr 02 20:06:42 GMT 2025

PRIMARY

INN

13117

Created by admin on Wed Apr 02 20:06:42 GMT 2025 , Edited by admin on Wed Apr 02 20:06:42 GMT 2025

PRIMARY

CAS

2857858-76-3

Created by admin on Wed Apr 02 20:06:42 GMT 2025 , Edited by admin on Wed Apr 02 20:06:42 GMT 2025

PRIMARY

From	To
1_275	2_275
1_272	2_272
1_34	1_112
2_34	2_112
1_413	1_471
2_413	2_471
1_307	1_367
2_307	2_367
1_178	1_240
2_178	2_240
1_155	1_228
2_155	2_228
1_22	1_96
2_22	2_96

Related Record Type Details


					ZK6M4PA6QA

COAGULATION FACTOR XI

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					L55HB62LXD

Lofacimig

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID REMOVAL	[1_493] [2_493]	C-TERMINUS	K		LYSINE	K3Z4F929H6
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS	Q		PIDOLIC ACID	SZB83O1W42

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL